Cargando…
A Cross-Sectional Comparison of Druggable Mutations in Primary Tumors, Metastatic Tissue, Circulating Tumor Cells, and Cell-Free Circulating DNA in Patients with Metastatic Breast Cancer: The MIRROR Study Protocol
BACKGROUND: Characterization of the driver mutations in an individual metastatic breast cancer (MBC) patient is critical to selecting effective targeted therapies. Currently, it is believed that the limited efficacy of many targeted drugs may be due to the expansion of drug resistant clones with dif...
Autores principales: | Gonzalez-Rivera, Milagros, Picornell, Antoni C, Alvarez, Enrique L, Martin, Miguel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
JMIR Publications
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5005674/ https://www.ncbi.nlm.nih.gov/pubmed/27531554 http://dx.doi.org/10.2196/resprot.6024 |
Ejemplares similares
-
Circulating tumor cells mirror bone metastatic phenotype in prostate cancer
por: Josefsson, Andreas, et al.
Publicado: (2018) -
The Discordance of Gene Mutations between Circulating Tumor Cells and Primary/Metastatic Tumor
por: Wang, Qi, et al.
Publicado: (2019) -
Monitoring BRAF and NRAS mutations with cell-free circulating tumor DNA from metastatic melanoma patients
por: Long-Mira, Elodie, et al.
Publicado: (2018) -
Non‐invasive analysis of tumor mutation profiles and druggable mutations by sequencing of cell free DNA of Chinese metastatic breast cancer patients
por: Li, Shunying, et al.
Publicado: (2019) -
The Tumor Microenvironment: A Druggable Target for Metastatic Disease?
por: EBioMedicine
Publicado: (2018)